Obinutuzumab

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: Chronic Lymphocytic Leukemia, Follicular Lymphoma, Lupus Nephritis, Primary Membranous Nephropathy

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Non-Hodgkin Lymphoma · Phase 3

Also approved (5)
US
  • To reduce the risk of relapse in adult and pediatric patients 2 years of age and older with frequently relapsing or steroid-dependent childhood-onset idiopathic nephrotic syndrome who are in complete remissionFDA label
  • GAZYVA is indicated to reduce the risk of relapse in adult and pediatric patients 2 years of age and older with frequently relapsing or steroid dependent childhood-onset idiopathic nephrotic syndrome who are in complete remission.dailymed.nlm.nih.gov
Product first approved 2013Outside this platform's coverage
EU
  • in combination with mycophenolate mofetil for adult patients with active Class III or IV, with or without concomitant Class V, lupus nephritisroche.com
  • Chronic lymphocytic leukaemia (CLL) Gazyvaro in combination with chlorambucil is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy. Follicular Lymphoma (FL) Gazyvaro in combination with chemotherapy, followed by Gazyvaro maintenance therapy in patients achieving a response, is indicated for the treatment of patients with previously untreated advanced follicular lymphoma. Gazyvaro in combination with bendamustine followed by Gazyvaro maintenance is...
    EMA
Product first approved 2014
JP
  • Treatment of CD20-positive follicular lymphoma
Product first approved 2018PMDA

Company guidance: data expected November 2026 (NCT04629248; Roche, 23 Jul 2026). “The priority review is based on the positive phase III MAJESTY results, which show superiority of Gazyva/Gazyvaro over an immunosuppressive therapy, tacrolimus, in adults with pMN. 1 The FDA has already granted Breakthrough Therapy Designation (BTD) to Gazyva/Gazyvaro in pMN and is expected to make a decision on approval by November 2026.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (36)
Chronic Lymphocytic Leukemia
NCT05057494 · AstraZeneca
2022-09-12 – 2029-04-10 · Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
What this study did
NCT04269902 · National Cancer Institute (NCI)
2021-03-02 – 2028-10-01 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT03701282 · National Cancer Institute (NCI)
2019-02-12 – 2028-05-07 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT05197192 · German CLL Study Group
2022-04-19 – 2028-05 · Chronic Lymphocytic Leukemia
What this study did
NCT03836261 · Acerta Pharma BV
2019-02-25 – 2027-04-30 · Chronic Lymphocytic Leukemia
What this study did
NCT03737981 · National Cancer Institute (NCI)
2019-01-31 – 2026-12-29 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT02475681 · Acerta Pharma BV
2015-06-26 – 2026-09-03 · Chronic Lymphocytic Leukemia
What this study did
NCT03406156 · AbbVie
2018-08-10 – 2023-07-12 · Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
What this study did
NCT01905943 · Hoffmann-La Roche
2013-11-04 – 2018-10-08 · Chronic Lymphocytic Leukemia
What this study did
NCT01998880 · Hoffmann-La Roche
2009-12-22 – 2017-08-23 · Lymphocytic Leukemia, Chronic
What this study did
NCT02053610 · Hoffmann-La Roche
2009-12-31 – 2017-08-23 · Lymphocytic Leukemia, Chronic
What this study did
Follicular Lymphoma
NCT05929222 · Fondazione Italiana Linfomi - ETS
2023-12-14 – 2031-04 · Follicular Lymphoma
What this study did
NCT05100862 · BeOne Medicines
2022-03-10 – 2030-06 · Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
What this study did
Lupus Nephritis
NCT07767188 · Zhao Minghui
2026-09-10 – 2029-05-08 · Lupus Nephritis
What this study did
Non-Hodgkin Lymphoma
Primary Membranous Nephropathy
NCT06120673 · The University of Queensland
2025-10-31 – 2028-01-31 · Primary Membranous Nephropathy
What this study did
Other / comorbidity
NCT06084936 · Hoffmann-La Roche
2023-10-22 – 2028-03-31 · Lymphoma
What this study did
NCT04963296 · Hoffmann-La Roche
2021-10-26 – 2028-03-13 · Systemic Lupus Erythematosus
What this study did
NCT05627557 · Hoffmann-La Roche
2023-03-29 – 2026-08-27 · Childhood Idiopathic Nephrotic Syndrome
What this study did
NCT01287741 · Hoffmann-La Roche
2011-07-26 – 2018-01-31 · Diffuse Large B-Cell Lymphoma
What this study did
NCT01659099 · The Lymphoma Academic Research Organisation
2012-09 – 2017-12-31 · Diffuse Large B Cell Lymphoma CD20 Positive
What this study did
Phase 2/3 (3)
Other / comorbidity
NCT07724457 · National Cancer Institute (NCI)
2027-07-27 – 2033-11-01 · Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Refractory Burkitt Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
What this study did
NCT07163611 · Radboud University Medical Center
2025-10-01 – 2028-04-01 · Membranous Nephropathy - PLA2R Induced
What this study did
NCT05786768 · Assistance Publique - Hôpitaux de Paris
2023-10-18 – 2027-06-30 · Steroid-Dependent Nephrotic Syndrome, Steroid-Sensitive Nephrotic Syndrome
What this study did
Phase 2 (163)
Chronic Lymphocytic Leukemia
NCT03516617 · Mayo Clinic
2018-09-10 – 2036-11-11 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT06978088 · Zulfa Omer
2025-06-01 – 2034-06-01 · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma, CLL/SLL, Chronic Lymphocytic Leukemia
What this study did
NCT07624799 · French Innovative Leukemia Organisation
2026-09-01 – 2033-09-01 · CLL (Chronic Lymphocytic Leukemia)
What this study did
NCT06967610 · M.D. Anderson Cancer Center
2025-07-15 – 2033-06-01 · Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia (SLL)
What this study did
NCT06043674 · Christine Ryan
2024-01-22 – 2033-01-15 · Chronic Lymphocytic Leukemia, Richter's Transformation
What this study did
NCT06333262 · Inhye Ahn
2024-04-22 – 2032-07-01 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT07887061 · Fred Hutchinson Cancer Center
2027-01-01 – 2032-07-01 · Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
What this study did
NCT06544785 · PETHEMA Foundation
2024-09-02 – 2032-05-31 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT07690891 · Medical College of Wisconsin
2026-10-01 – 2031-09-01 · Chronic Lymphocytic Leukemia
What this study did
NCT06849713 · Massachusetts General Hospital
2025-05-16 – 2030-03-01 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (SLL)
What this study did
NCT07218510 · City of Hope Medical Center
2026-01-07 – 2029-06-08 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT07674810 · M.D. Anderson Cancer Center
2026-12-31 – 2029-04-30 · Chronic Lymphocytic Leukemia
What this study did
NCT04560322 · Massachusetts General Hospital
2020-10-19 – 2029-03-01 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT04169737 · M.D. Anderson Cancer Center
2020-07-29 – 2028-07-09 · Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
What this study did
NCT07003464 · The First Hospital of Jilin University
2025-06-15 – 2028-06-01 · Chronic Lymphocytic Leukemia
What this study did
NCT02629809 · M.D. Anderson Cancer Center
2016-03-18 – 2028-03-31 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT03580928 · Dana-Farber Cancer Institute
2018-08-07 – 2027-12-31 · Chronic Lymphocytic Leukemia (CLL)
What this study did
NCT05650723 · Weill Medical College of Cornell University
2023-05-08 – 2027-12 · Leukemia, Lymphocytic, Chronic, B-Cell
What this study did
NCT04908228 · Paolo Ghia
2021-12-13 – 2027-09-15 · Chronic Lymphocytic Leukemia
What this study did
NCT04447768 · Memorial Sloan Kettering Cancer Center
2020-12-03 – 2027-07 · Chronic Lymphocytic Leukemia (CLL)
What this study did
NCT04505254 · M.D. Anderson Cancer Center
2020-08-25 – 2027-06-30 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT02846623 · M.D. Anderson Cancer Center
2017-01-31 – 2027-02-28 · Chronic Lymphocytic Leukemia, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma
What this study did
NCT04722172 · Memorial Sloan Kettering Cancer Center
2021-05-21 – 2027-02 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT03824483 · Memorial Sloan Kettering Cancer Center
2019-02-22 – 2027-02 · Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL)
What this study did
NCT05336812 · Ohio State University Comprehensive Cancer Center
2022-09-13 – 2026-10-31 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT05322733 · The First Affiliated Hospital with Nanjing Medical University
2022-04-15 – 2025-11-05 · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
What this study did
NCT02371590 · University of California, San Diego
2018-02 – 2022-12 · Chronic Lymphocytic Leukemia
What this study did
NCT02225275 · M.D. Anderson Cancer Center
2016-03-31 – 2021-05-19 · Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
What this study did
NCT03755947 · Grupo Cooperativo de Hemopatías Malignas
2018-12-01 – 2021-02-01 · B-Cell Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia in Relapse (Diagnosis)
What this study did
NCT02983617 · Gilead Sciences
2017-04-06 – 2020-10-01 · Chronic Lymphocytic Leukemia
What this study did
NCT03153514 · German CLL Study Group
2017-11-13 – 2019-06-06 · Chronic Lymphocytic Leukemia, Richter's Transformation
What this study did
NCT02320487 · Genentech, Inc.
2015-03-31 – 2019-02-06 · Chronic Lymphocytic Leukemia
What this study did
NCT02071225 · Hoffmann-La Roche
2014-04-09 – 2018-11-19 · Chronic Lymphocytic Leukemia
What this study did
NCT01414205 · Genentech, Inc.
2011-10-31 – 2016-03-31 · Lymphocytic Leukemia, Chronic
What this study did
NCT01868893 · Genentech, Inc.
2013-08 – 2014-01 · Chronic Lymphocytic Leukemia
What this study did
Follicular Lymphoma
NCT07299149 · Institute of Hematology & Blood Diseases Hospital, China
2025-12-25 – 2030-12-25 · Follicular Lymphoma
What this study did
NCT06961500 · Sun Yat-sen University
2025-05-01 – 2030-11-01 · Follicular Lymphoma Grade 3A
What this study did
NCT06918015 · Zhejiang Cancer Hospital
2025-05-01 – 2030-05-01 · BTK Inhibitors, Follicular Lymphoma, Immunochemotherapy
What this study did
NCT06474481 · Tianjin Medical University Cancer Institute and Hospital
2024-07 – 2029-12 · FL
What this study did
NCT06959732 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2025-01-01 – 2027-12-31 · Follicular Lymphoma ( FL)
What this study did
NCT06108232 · M.D. Anderson Cancer Center
2024-03-15 – 2027-12-31 · Follicular Lymphoma, Tumor
What this study did
NCT06553352 · The First Affiliated Hospital of Xiamen University
2024-03-31 – 2027-08-31 · Follicular Lymphoma, Newly Diagnosed
What this study did
NCT04962126 · Olivia Newton-John Cancer Research Institute
2021-08-17 – 2027-07 · Follicular Lymphoma
What this study did
NCT04450173 · University of California, Davis
2021-02-24 – 2027-04 · Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
What this study did
NCT03269669 · National Cancer Institute (NCI)
2018-01-23 – 2027-01-21 · Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
What this study did
Phase 1/2 (44)
Chronic Lymphocytic Leukemia
NCT07520006 · Nurix Therapeutics, Inc.
2026-09-30 – 2033-05 · B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT02427451 · Kerry Rogers
2015-08-03 – 2027-04-15 · Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
What this study did
NCT07847957 · Dana-Farber Cancer Institute
2027-01-13 – 2027-04-01 · Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia
What this study did
NCT06762431 · Vitebsk Regional Clinical Cancer Centre
2024-05-14 – 2026-08-31 · Chronic Lymphocytic Leukaemia (CLL), Small Lymphocytic Lymphoma (SLL)
What this study did
NCT02229422 · University of California, San Diego
2014-09 – 2025-12-25 · CLL
What this study did
NCT03492125 · MingSight Pharmaceuticals, Inc
2018-05-25 – 2023-11-28 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma
What this study did
NCT02315768 · University of California, San Diego
2015-08-26 – 2022-04-18 · Chronic Lymphocytic Leukemia
What this study did
NCT03010358 · Alexey Danilov, MD
2017-07-17 – 2021-04-29 · Anemia, B-Cell Prolymphocytic Leukemia, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Hairy Cell Leukemia, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma, Richter Syndrome
What this study did
Follicular Lymphoma
NCT03980171 · Peter MacCallum Cancer Centre, Australia
2019-08-19 – 2026-11 · Follicular Lymphoma
What this study did
NCT04722601 · University of Chicago
2021-09-01 – 2023-03-31 · Follicular Lymphoma
What this study did
NCT01582776 · The Lymphoma Academic Research Organisation
2012-10-03 – 2022-05-20 · Follicular Lymphoma Patients (Phase IB), Follicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II)
What this study did
NCT02600897 · Hoffmann-La Roche
2016-03-24 – 2021-12-15 · Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
What this study did
NCT02391545 · SecuraBio
2014-12 – 2017-05 · CD20+ Follicular Lymphoma
What this study did
Non-Hodgkin Lymphoma
NCT05533775 · Hoffmann-La Roche
2022-11-16 – 2032-11-30 · Mature B-Cell Non-Hodgkin Lymphoma
What this study did
NCT03223610 · National Cancer Institute (NCI)
2018-02-09 – 2029-12-12 · Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma
What this study did
NCT06090539 · Bristol-Myers Squibb
2023-12-29 – 2028-10-28 · Relapsed/Refractory Non-Hodgkin Lymphoma
What this study did
NCT03533283 · Hoffmann-La Roche
2018-05-08 – 2026-10-22 · Non-Hodgkins Lymphoma
What this study did
NCT01995669 · M.D. Anderson Cancer Center
2014-05-27 – 2023-01-23 · Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Follicular Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma
What this study did
NCT02611323 · Hoffmann-La Roche
2016-03-09 – 2022-08-04 · Non-Hodgkin's Lymphoma
What this study did
Other / comorbidity
NCT07696377 · Zhongming Qiu
2026-07-15 – 2031-02-28 · Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Obinutuzumab β
What this study did
NCT07441954 · Institute of Hematology & Blood Diseases Hospital, China
2026-03-20 – 2029-12-31 · Indolent Lymphoma
What this study did
NCT06634589 · BeOne Medicines
2024-11-27 – 2029-12-02 · B-cell Malignancy, Relapsed Cancer, Refractory Cancer, B-cell Lymphoma
What this study did
NCT06357676 · OHSU Knight Cancer Institute
2025-05-29 – 2029-11-01 · Mantle Cell Lymphoma
What this study did
NCT04855695 · Austin I Kim
2021-07-02 – 2027-12-31 · Mantle Cell Lymphoma, Refractory Lymphoma
What this study did
NCT06592170 · The First Hospital of Jilin University
2024-08-13 – 2027-08-13 · Lymphoma
What this study did
NCT05861050 · City of Hope Medical Center
2023-08-10 – 2027-02-01 · Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma
What this study did
NCT04787042 · Simcha IL-18, Inc.
2021-08-06 – 2025-12-31 · Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Carcinoma, MSI-High
What this study did
NCT02558816 · Nantes University Hospital
2015-10-14 – 2025-05-13 · Mantle Cell Lymphoma
What this study did
NCT02529852 · M.D. Anderson Cancer Center
2015-11-04 – 2022-10-31 · Lymphoma
What this study did
NCT00517530 · Hoffmann-La Roche
2007-09 – 2013-11 · Lymphoma
What this study did
Phase 1 (65)
Chronic Lymphocytic Leukemia
NCT04843904 · Dana-Farber Cancer Institute
2021-04-14 – 2030-06-02 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT05943496 · OHSU Knight Cancer Institute
2023-10-02 – 2028-01-01 · Chronic Lymphocytic Leukemia
What this study did
NCT06916767 · Paolo Caimi, MD
2025-07-15 – 2027-12-31 · Relapsed CLL, Refractory CLL, Refractory Lymphoma
What this study did
NCT06291220 · AbbVie
2025-01-27 – 2027-07 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT02537613 · Dana-Farber Cancer Institute
2015-12 – 2027-01 · Chronic Lymphocytic Leukemia
What this study did
NCT06547944 · Institute of Hematology & Blood Diseases Hospital, China
2024-01-01 – 2026-12-01 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Newly Diagnosed
What this study did
NCT02296918 · Acerta Pharma BV
2014-12-22 – 2025-10-22 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia
What this study did
NCT04578600 · Joseph Tuscano
2020-10-23 – 2025-02-21 · Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Mucosa-Associated Lymphoid Tissue Lymphoma, Recurrent Follicular Lymphoma, Recurrent Hairy Cell Leukemia, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mucosa-Associated Lymphoid Tissue Lymphoma, Refractory Follicular Lymphoma, Refractory Hairy Cell Leukemia, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Small Lymphocytic Lymphoma
What this study did
NCT04245722 · Fate Therapeutics
2020-03-19 – 2023-09-27 · Lymphoma, B-Cell, Chronic Lymphocytic Leukemia
What this study did
NCT01644253 · Aptevo Therapeutics
2012-09 – 2021-04-21 · Chronic Lymphocytic Leukemia, Peripheral T-cell Lymphoma
What this study did
NCT02611908 · Michael Choi
2016-06 – 2020-11 · Chronic Lymphocytic Leukemia
What this study did
NCT01685892 · Genentech, Inc.
2012-11-29 – 2019-08-23 · Lymphocytic Leukemia, Chronic
What this study did
NCT02100852 · TG Therapeutics, Inc.
2014-03-12 – 2017-11 · Chronic Lymphocytic Leukemia
What this study did
NCT01300247 · Genentech, Inc.
2011-05 – 2015-12 · Lymphocytic Leukemia, Chronic
What this study did
Follicular Lymphoma
NCT04599634 · National Cancer Institute (NCI)
2021-12-16 – 2024-06-20 · Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Lymphoma, B-Cell Lymphoma
What this study did
NCT02877550 · Swiss Cancer Institute
2017-02-15 – 2022-05-04 · Follicular Lymphoma
What this study did
NCT01680991 · Hoffmann-La Roche
2012-09 – 2014-12 · Lymphocytic Leukemia, Chronic, Diffuse Large B-cell Lymphoma, Follicular Lymphoma
What this study did
Lupus Nephritis
NCT06265220 · Artiva Biotherapeutics, Inc.
2024-04-03 – 2027-08 · Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Refractory Systemic Lupus Erythematosus, SLE
What this study did
Non-Hodgkin Lymphoma
NCT06824701 · University of Utah
2025-09-12 – 2033-01 · Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
What this study did
NCT04739813 · National Cancer Institute (NCI)
2021-07-09 – 2031-05-07 · Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma
What this study did
NCT04970901 · ADC Therapeutics S.A.
2022-06-17 – 2028-04-30 · B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
What this study did
NCT02992522 · Beth Christian
2017-02-21 – 2027-04-15 · B-Cell Lymphoma, Unspecified, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Transformed Recurrent Non-Hodgkin Lymphoma, B-Cell
What this study did
NCT05653271 · Acepodia Biotech, Inc.
2023-01-21 – 2026-03-31 · B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL, Primary Mediastinal Large B Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Burkitt Lymphoma, High-grade B-cell Lymphoma
What this study did
NCT03432741 · Mayo Clinic
2018-03-27 – 2022-10-03 · Breast Adenocarcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Recurrent Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Breast Carcinoma, Refractory Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Nodal Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IV Breast Cancer AJCC v6 and v7
What this study did
NCT02453087 · Hoffmann-La Roche
2015-08-04 – 2019-07-12 · Non-Hodgkin's Lymphoma
What this study did
NCT00825149 · Hoffmann-La Roche
2009-02 – 2015-11 · Non-Hodgkin's Lymphoma
What this study did
Other / comorbidity
NCT05211336 · National Cancer Institute (NCI)
2022-04-19 – 2029-06-01 · Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
What this study did
NCT07548255 · Ruijin Hospital
2026-04-20 – 2029-03-01 · Intermediate-to-High-Risk Mantle Cell Lymphoma, the Efficacy and Safety
What this study did
NCT06922604 · City of Hope Medical Center
2025-07-30 – 2029-01-02 · Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
What this study did
NCT07107490 · Chugai Pharmaceutical
2025-10-08 – 2028-09-30 · Extensive Stage Small Cell Lung Cancer
What this study did
NCT05894447 · Weill Medical College of Cornell University
2023-11 – 2028-06 · Urothelial Carcinoma
What this study did
NCT06192888 · Memorial Sloan Kettering Cancer Center
2024-01-08 – 2028-01-08 · Mantle Cell Lymphoma, MCL
What this study did
NCT04277637 · BeOne Medicines
2020-03-24 – 2027-05-31 · Mature B-Cell Malignancies
What this study did
NCT06624085 · Hoffmann-La Roche
2025-04-28 – 2027-03-22 · Lymphoma
What this study did
NCT03983954 · NeoTX Therapeutics Ltd.
2019-10-10 – 2027-03-01 · ER+ Breast Cancer, Ovarian Cancer, Cervical Squamous Cell Carcinoma, Pancreatic Adenocarcinoma, Endometrial Cancer, Renal Cell Carcinoma, Urothelial Cancer, Head and Neck Squamous Cell Carcinoma, Mesothelioma, Melanoma, Hepatocellular Carcinoma, Prostate Cancer, NSCLC, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Bladder Cancer, Colorectal Cancer Metastatic, GastroEsophageal Cancer, NSCL2 Gene Mutation, Esophageal Cancer
What this study did
NCT05673057 · Molecular Partners AG
2022-12-29 – 2026-09-14 · Leukemia, Myeloid, Acute, Newly Diagnosed
What this study did
NCT03198650 · AstraZeneca
2017-06-27 – 2025-09-25 · Part1: Advanced B-cell Malignancies, Part2: r/rCLL and r/rMCL, Part3: Untreated CLL
What this study did
NCT04826003 · Hoffmann-La Roche
2021-07-14 – 2024-11-11 · Metastatic Colorectal Cancer
What this study did
NCT02457598 · Gilead Sciences
2015-06-16 – 2024-09-25 · B-cell Malignancies
What this study did
Phase 4 (2)
Follicular Lymphoma
NCT03817853 · Hoffmann-La Roche
2019-02-26 – 2023-01-25 · Advanced Follicular Lymphoma
What this study did
Lupus Nephritis
NCT07611214 · Aurinia Pharmaceuticals Inc.
2026-04-22 – 2029-03-02 · Lupus Nephritis
What this study did
Early phase / not applicable (3)
Chronic Lymphocytic Leukemia
NCT05950997 · The First Affiliated Hospital with Nanjing Medical University
2024-04-16 – 2026-09-30 · Chronic Lymphocytic Leukemia
What this study did
Follicular Lymphoma
NCT07126678 · The First Affiliated Hospital with Nanjing Medical University
2025-07-15 – 2028-12-30 · Follicular Lymphoma, Treatment Naive
What this study did
Non-Hodgkin Lymphoma
NCT05797948 · The First Affiliated Hospital of Soochow University
2022-07-01 – 2024-06-30 · Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
What this study did
Used as active comparator (7)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (5)
Chronic Lymphocytic Leukemia
NCT06970743 · BeOne Medicines
2025-05-29 – 2029-11-30 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT03462719 · Janssen Research & Development, LLC
2018-04-17 – 2029-04-05 · Leukemia, Lymphocytic, Chronic, B-Cell
What this study did
NCT02612311 · TG Therapeutics, Inc.
2015-11-19 – 2023-02-22 · Chronic Lymphocytic Leukemia
What this study did
Follicular Lymphoma
NCT06284122 · The Lymphoma Academic Research Organisation
2024-06-07 – 2034-04 · Follicular Lymphoma
What this study did
Phase 2 (1)
Follicular Lymphoma
NCT05848765 · University of Birmingham
2023-09-04 – 2031-11-30 · Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma
What this study did
Phase 1 (1)
Non-Hodgkin Lymphoma
Appears in other studies (3)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (2)
Chronic Lymphocytic Leukemia
NCT02242942 · Hoffmann-La Roche
2014-12-31 – 2025-08-27 · Lymphocytic Leukemia, Chronic
What this study did
Follicular Lymphoma
NCT04796922 · Incyte Corporation
2022-12-30 – 2032-08-25 · Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL)
What this study did
Phase 2 (1)
Other / comorbidity
NCT04880863 · NeoTX Therapeutics Ltd.
2021-10-26 – 2024-01-30 · Non-small Cell Lung Cancer
What this study did

Competitive landscape

This mechanism is crowded: 15 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Chronic Lymphocytic Leukemia: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Obinutuzumab: this drugApprovedMonoclonal antibodyCD20Partial signalNo reviewed efficacy summary in this indication
AcalabrutinibApprovedSmall moleculeBTKPartial signalFeatured results are non-efficacy only in this race
AlemtuzumabApprovedMonoclonal antibodyCD52not yet gradedNo reviewed efficacy summary in this indication
IbrutinibApprovedSmall moleculeBTKPartial signal
NCT01611090: Progression-free Survival (PFS) (Up to 5 years): Ibrutinib+BR 65.12 Months | Placebo+BR 14.32 Months (95% CI 13.86 to 16.62)
Ocrelizumab
Approved(overall)
Monoclonal antibodyCD20
Reliable signal(overall)
No reviewed efficacy summary in this indication
Ocrevus Zunovo
Approved(overall)
Monoclonal antibodyCD20
not yet graded(overall)
No reviewed efficacy summary in this indication
Ofatumumab
Approved(overall)
Monoclonal antibodyCD20
Reliable signal(overall)
No reviewed efficacy summary in this indication
PF-05280586ApprovedBiologic (subtype unspecified)CD20not yet gradedNo reviewed efficacy summary in this indication
PirtobrutinibApprovedSmall moleculeBTKPartial signalFeatured results are non-efficacy only in this race
Rituximab (Rituxan)ApprovedMonoclonal antibodyCD20, CD20-directed Cytolytic Antibodynot yet gradedNo reviewed efficacy summary in this indication
Rituximab-Abbs (Truxima)ApprovedMonoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
Ublituximab (Briumvi)
Approved(overall)
Monoclonal antibodyCD20
Reliable signal(overall)
No reviewed efficacy summary in this indication
VenetoclaxApprovedSmall moleculeBCL-2Partial signal
NCT02005471: Investigator-assessed PFS, venetoclax-rituximab vs bendamustine-rituximab: 2-year rates 84.9% vs 36.3% (hazard ratio 0.17; P<0.001)
Zanubrutinib (Brukinsa)ApprovedSmall moleculeBTKPartial signal
NCT03734016: Overall response rate, zanubrutinib (n=327) vs ibrutinib (n=325): by independent review 86.2% vs 75.7%, response ratio 1.14 (95% CI 1.05 to 1.22), non-inferiority p<0.0001, superiority p=0.0007; by investigator 83.5% vs 74.2%, response ratio 1.12 (95% CI 1.04 to 1.22), non-inferiority p<0.0001, superiority p=0.0035 (CT.gov posted results).
ABP 692
Phase 3(overall)
Monoclonal antibodyCD20
not yet graded(overall)
No reviewed efficacy summary in this indication
Acellbia
Phase 3(overall)
Monoclonal antibodyCD20
Reliable signal(overall)
No reviewed efficacy summary in this indication
BCD-281
Phase 3(overall)
Monoclonal antibodyCD20
not yet graded(overall)
No reviewed efficacy summary in this indication
BexobrutidegPhase 3Small moleculeBruton's tyrosine kinase (BTK)not yet gradedNo reviewed efficacy summary in this indication
CT-P53
Phase 3(overall)
Monoclonal antibodyCD20
not yet graded(overall)
No reviewed efficacy summary in this indication
Divozilimab (Ivlizi)
Phase 3(overall)
Monoclonal antibodyCD20
Reliable signal(overall)
No reviewed efficacy summary in this indication
HLX01 (Hanlikang)
Phase 3(overall)
Monoclonal antibodyCD20
Reliable signal(overall)
No reviewed efficacy summary in this indication
NemtabrutinibPhase 3Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Sonrotoclax (Beqalzi)Phase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MesutoclaxPhase 2/3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MS-553Phase 1/2Small moleculeProtein kinase C-beta (PKC-beta)not yet gradedNo reviewed efficacy summary in this indication
SAR448501
Phase 1(overall)
Multispecific antibodyCD20
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(134 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Obinutuzumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (8)
November 2026 (2)
Phase 1/2Follicular LymphomaActive not recruiting
Est. primary completion 2026-11 · NCT03980171 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2026-11 · NCT04895436 · CT.gov ↗
What to watch
December 2026 (6)
Phase 2Fibrillary GlomerulonephritisRecruiting
Est. primary completion 2026-12 · NCT06295770 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2026-12 · NCT02393157 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaNot yet recruiting
Est. primary completion 2026-12-01 · NCT06549335 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaNot yet recruiting
Est. primary completion 2026-12-01 · NCT06656221 · CT.gov ↗
What to watch
Phase 1/2Non-Hodgkin LymphomaActive not recruiting
Est. primary completion 2026-12-28 · NCT04077723 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaActive not recruiting
Est. primary completion 2026-12-31 · NCT06504199 · CT.gov ↗
What to watch
2027 (53)
January 2027 (3)
Phase 2Marginal Zone LymphomaActive not recruiting
Est. primary completion 2027-01 · NCT03322865 · CT.gov ↗
What to watch
Phase 2Hairy Cell Leukemia, Leukemia, Leukemia, Hairy CellActive not recruiting
Est. primary completion 2027-01 · NCT03410875 · CT.gov ↗
What to watch
Phase 1Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2027-01-01 · NCT05943496 · CT.gov ↗
What to watch
February 2027 (5)
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-02 · NCT04722172 · CT.gov ↗
What to watch
Phase 2Chronic Lymphoid LeukemiaActive not recruiting
Est. primary completion 2027-02 · NCT04515238 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-02 · NCT03824483 · CT.gov ↗
What to watch
Phase 1/2Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell LymphomaRecruiting
Est. primary completion 2027-02-01 · NCT05861050 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-02-28 · NCT02846623 · CT.gov ↗
What to watch
March 2027 (4)
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-03 · NCT05650723 · CT.gov ↗
What to watch
Phase 1ER+ Breast Cancer, Ovarian Cancer, Cervical Squamous Cell Carcinoma, Pancreatic Adenocarcinoma, Endometrial Cancer, Renal Cell Carcinoma …Active not recruiting
Est. primary completion 2027-03-01 · NCT03983954 · CT.gov ↗
What to watch
Phase 1LymphomaActive not recruiting
Est. primary completion 2027-03-22 · NCT06624085 · CT.gov ↗
What to watch
Phase 1Non-Hodgkin LymphomaActive not recruiting
Est. primary completion 2027-03-31 · NCT04970901 · CT.gov ↗
What to watch
April 2027 (5)
Phase 2Follicular LymphomaActive not recruiting
Est. primary completion 2027-04 · NCT04450173 · CT.gov ↗
What to watch
Phase 1/2Chronic Lymphocytic LeukemiaNot yet recruiting
Est. primary completion 2027-04-01 · NCT07847957 · CT.gov ↗
What to watch
Phase 1/2Non-Hodgkin LymphomaActive not recruiting
Est. primary completion 2027-04-07 · NCT03930953 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaNot yet recruiting
Est. primary completion 2027-04-30 · NCT07674810 · CT.gov ↗
What to watch
Phase 3Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-04-30 · NCT03836261 · CT.gov ↗
What to watch
May 2027 (1)
Phase 1Mature B-Cell MalignanciesActive not recruiting
Est. primary completion 2027-05-31 · NCT04277637 · CT.gov ↗
What to watch
June 2027 (8)
Phase 2Chronic Lymphocytic LeukemiaNot yet recruiting
Est. primary completion 2027-06-01 · NCT07003464 · CT.gov ↗
What to watch
Phase 2Marginal Zone LymphomaActive not recruiting
Est. primary completion 2027-06-21 · NCT06513234 · CT.gov ↗
What to watch
Phase 1Mature B-cell MalignanciesRecruiting
Est. primary completion 2027-06-25 · NCT06351527 · CT.gov ↗
What to watch
Phase 1/2Mantle Cell Lymphoma, Refractory LymphomaRecruiting
Est. primary completion 2027-06-30 · NCT04855695 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2027-06-30 · NCT06959732 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-06-30 · NCT04505254 · CT.gov ↗
What to watch
Phase 2Multi Center, Phase 2, Golcadomide, Glofitamab, Polauzumab, Vedotin, G2p, B Cell LymphomaNot yet recruiting
Est. primary completion 2027-06-30 · NCT07917832 · CT.gov ↗
What to watch
Phase 2/3Steroid-Dependent Nephrotic Syndrome, Steroid-Sensitive Nephrotic SyndromeActive not recruiting
Est. primary completion 2027-06-30 · NCT05786768 · CT.gov ↗
What to watch
July 2027 (10)
Phase 1Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-07 · NCT06291220 · CT.gov ↗
What to watch
Phase 2DLBCL - Diffuse Large B Cell LymphomaNot yet recruiting
Est. primary completion 2027-07 · NCT07326371 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-07 · NCT04447768 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2027-07-01 · NCT06333262 · CT.gov ↗
What to watch
Phase 2Marginal Zone LymphomaRecruiting
Est. primary completion 2027-07-08 · NCT06504940 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2027-07-13 · NCT06054776 · CT.gov ↗
What to watch
Phase 3Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-07-15 · NCT05057494 · CT.gov ↗
What to watch
Phase 2Large B-cell LymphomaRecruiting
Est. primary completion 2027-07-30 · NCT06071871 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2027-07-31 · NCT07261163 · CT.gov ↗
What to watch
Phase 2B Cell LymphomaRecruiting
Est. primary completion 2027-07-31 · NCT06213311 · CT.gov ↗
What to watch
August 2027 (5)
Phase 1Lupus NephritisActive not recruiting
Est. primary completion 2027-08 · NCT06265220 · CT.gov ↗
What to watch
Phase 1/2Non-Hodgkin LymphomaRecruiting
Est. primary completion 2027-08-12 · NCT03223610 · CT.gov ↗
What to watch
Phase 2DLBCL - Diffuse Large B Cell Lymphoma, Richter Transformation, CLL / SLL, MZLNot yet recruiting
Est. primary completion 2027-08-31 · NCT07744750 · CT.gov ↗
What to watch
Phase 2Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell LymphomaRecruiting
Est. primary completion 2027-08-31 · NCT07003295 · CT.gov ↗
What to watch
Phase 3LymphomaRecruiting
Est. primary completion 2027-08-31 · NCT06084936 · CT.gov ↗
What to watch
September 2027 (3)
Phase 2Large B-cell LymphomaNot yet recruiting
Est. primary completion 2027-09 · NCT06567366 · CT.gov ↗
What to watch
Phase 3Chronic Lymphoid LeukemiaActive not recruiting
Est. primary completion 2027-09 · NCT04608318 · CT.gov ↗
What to watch
Phase 2Hairy Cell LeukemiaRecruiting
Est. primary completion 2027-09-09 · NCT06561360 · CT.gov ↗
What to watch
October 2027 (1)
Phase 1/2Non-Hodgkin LymphomaRecruiting
Est. primary completion 2027-10-28 · NCT06090539 · CT.gov ↗
What to watch
November 2027 (1)
Phase 1/2Mantle Cell LymphomaRecruiting
Est. primary completion 2027-11-01 · NCT06357676 · CT.gov ↗
What to watch
December 2027 (7)
Phase 2Follicular LymphomaNot yet recruiting
Est. primary completion 2027-12 · NCT06474481 · CT.gov ↗
What to watch
Phase 2Granulomatosis With PolyangiitisRecruiting
Est. primary completion 2027-12 · NCT06940661 · CT.gov ↗
What to watch
Phase 1/2Indolent LymphomaNot yet recruiting
Est. primary completion 2027-12-05 · NCT07441954 · CT.gov ↗
What to watch
Phase 2Lymphoma, Mantle-Cell, Lymphoma, Non-HodgkinNot yet recruiting
Est. primary completion 2027-12-30 · NCT06427213 · CT.gov ↗
What to watch
Phase 1Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2027-12-31 · NCT06916767 · CT.gov ↗
What to watch
Phase 2Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell LymphomaActive not recruiting
Est. primary completion 2027-12-31 · NCT04889716 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2027-12-31 · NCT06108232 · CT.gov ↗
What to watch
2028 (42)
January 2028 (4)
Phase 2Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell LymphomaRecruiting
Est. primary completion 2028-01 · NCT06765317 · CT.gov ↗
What to watch
Phase 2Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Active not recruiting
Est. primary completion 2028-01-01 · NCT07480850 · CT.gov ↗
What to watch
Phase 1Mantle Cell Lymphoma, MCLActive not recruiting
Est. primary completion 2028-01-08 · NCT06192888 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-01-15 · NCT06043674 · CT.gov ↗
What to watch
March 2028 (6)
Phase 3Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-03 · NCT06428019 · CT.gov ↗
What to watch
Phase 2Richter SyndromeRecruiting
Est. primary completion 2028-03-01 · NCT06186648 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-03-01 · NCT06849713 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2028-03-01 · NCT04560322 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2028-03-31 · NCT02629809 · CT.gov ↗
What to watch
Phase 3Diffuse Large B-cell LymphomaActive not recruiting
Est. primary completion 2028-03-31 · NCT04408638 · CT.gov ↗
What to watch
April 2028 (3)
Phase 2/3Membranous Nephropathy - PLA2R InducedRecruiting
Est. primary completion 2028-04-01 · NCT07163611 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-04-25 · NCT05536349 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2028-04-28 · NCT07299149 · CT.gov ↗
What to watch
May 2028 (6)
Phase 2Lymphoma, Mantle-CellRecruiting
Est. primary completion 2028-05 · NCT06558604 · CT.gov ↗
What to watch
Phase 3Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-05 · NCT05197192 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaNot yet recruiting
Est. primary completion 2028-05-01 · NCT06918015 · CT.gov ↗
What to watch
Phase 3Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2028-05-07 · NCT03701282 · CT.gov ↗
What to watch
Phase 2Cryoglobulinemic Vasculitis (CV)Recruiting
Est. primary completion 2028-05-31 · NCT07268521 · CT.gov ↗
What to watch
Phase 3Primary Membranous NephropathyRecruiting
Est. primary completion 2028-05-31 · NCT06781944 · CT.gov ↗
What to watch
June 2028 (2)
Phase 2Lupus NephritisRecruiting
Est. primary completion 2028-06-15 · NCT05039619 · CT.gov ↗
What to watch
Phase 2Minimal Change Disease (MCD)Recruiting
Est. primary completion 2028-06-30 · NCT07710157 · CT.gov ↗
What to watch
July 2028 (4)
Phase 3Follicular LymphomaActive not recruiting
Est. primary completion 2028-07 · NCT05100862 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-07-09 · NCT04169737 · CT.gov ↗
What to watch
Early phase / not applicableFollicular LymphomaRecruiting
Est. primary completion 2028-07-15 · NCT07126678 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2028-07-31 · NCT06252675 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), LymphomaRecruiting
Est. primary completion 2028-08-31 · NCT06867536 · CT.gov ↗
What to watch
September 2028 (6)
Phase 2Mantle Cell LymphomaNot yet recruiting
Est. primary completion 2028-09 · NCT07799220 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaNot yet recruiting
Est. primary completion 2028-09-01 · NCT07624799 · CT.gov ↗
What to watch
Phase 2High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma …Recruiting
Est. primary completion 2028-09-01 · NCT06649812 · CT.gov ↗
What to watch
Phase 2Primary Central Nervous System LymphomaRecruiting
Est. primary completion 2028-09-15 · NCT06175000 · CT.gov ↗
What to watch
Phase 2Lymphoma, B-cell Lymphomas, Relapsed/Refractory Large B-cell Lymphoma, Large B-cell LymphomaRecruiting
Est. primary completion 2028-09-15 · NCT07711483 · CT.gov ↗
What to watch
Phase 1Extensive Stage Small Cell Lung CancerRecruiting
Est. primary completion 2028-09-30 · NCT07107490 · CT.gov ↗
What to watch
October 2028 (2)
Phase 2Non-Hodgkin LymphomaRecruiting
Est. primary completion 2028-10-01 · NCT07883135 · CT.gov ↗
What to watch
Phase 3Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-10-01 · NCT04269902 · CT.gov ↗
What to watch
November 2028 (2)
Phase 2Relapsed/Refractory Large B-cell Lymphoma (LBCL)Not yet recruiting
Est. primary completion 2028-11 · NCT07613788 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-11-11 · NCT03516617 · CT.gov ↗
What to watch
December 2028 (6)
Phase 2PCNSL (Primary CNS Lymphoma), Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma (SCNSL)Not yet recruiting
Est. primary completion 2028-12 · NCT07888621 · CT.gov ↗
What to watch
Phase 1/2B-cell Malignancy, Relapsed Cancer, Refractory Cancer, B-cell LymphomaRecruiting
Est. primary completion 2028-12-02 · NCT06634589 · CT.gov ↗
What to watch
Phase 2Large B-cell Lymphoma, TP53Recruiting
Est. primary completion 2028-12-30 · NCT07240194 · CT.gov ↗
What to watch
Phase 2Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli,SBLPNRecruiting
Est. primary completion 2028-12-31 · NCT07165769 · CT.gov ↗
What to watch
Phase 2Marginal Zone Lymphoma(MZL)Recruiting
Est. primary completion 2028-12-31 · NCT06793189 · CT.gov ↗
What to watch
Phase 2Large B-Cell Lymphoma (LBCL), High-grade B-cell LymphomaNot yet recruiting
Est. primary completion 2028-12-31 · NCT07774234 · CT.gov ↗
What to watch
2029 (16)
January 2029 (1)
Phase 1Primary Central Nervous System Lymphoma, Secondary Central Nervous System LymphomaRecruiting
Est. primary completion 2029-01-02 · NCT06922604 · CT.gov ↗
What to watch
February 2029 (1)
Phase 3Lupus NephritisNot yet recruiting
Est. primary completion 2029-02-27 · NCT07767188 · CT.gov ↗
What to watch
March 2029 (4)
Phase 2Nephrotic Syndrome,IdiopathicNot yet recruiting
Est. primary completion 2029-03 · NCT07233330 · CT.gov ↗
What to watch
Phase 1Intermediate-to-High-Risk Mantle Cell Lymphoma, the Efficacy and SafetyNot yet recruiting
Est. primary completion 2029-03-01 · NCT07548255 · CT.gov ↗
What to watch
Phase 4Lupus NephritisRecruiting
Est. primary completion 2029-03-02 · NCT07611214 · CT.gov ↗
What to watch
Phase 1/2Non-Hodgkin LymphomaActive not recruiting
Est. primary completion 2029-03-30 · NCT03075696 · CT.gov ↗
What to watch
April 2029 (1)
Phase 1Non-Hodgkin LymphomaActive not recruiting
Est. primary completion 2029-04-30 · NCT05169515 · CT.gov ↗
What to watch
June 2029 (2)
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2029-06-01 · NCT06978088 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2029-06-08 · NCT07218510 · CT.gov ↗
What to watch
July 2029 (2)
Phase 2Mantle Cell Lymphoma (MCL)Recruiting
Est. primary completion 2029-07-01 · NCT07719556 · CT.gov ↗
What to watch
Phase 2Relapsed or Refractory Aggressive B-Cell Non-Hodgkins LymphomaRecruiting
Est. primary completion 2029-07-31 · NCT06806033 · CT.gov ↗
What to watch
September 2029 (2)
Phase 2Lupus NephritisNot yet recruiting
Est. primary completion 2029-09-02 · NCT07721363 · CT.gov ↗
What to watch
Phase 3Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2029-09-30 · NCT06943872 · CT.gov ↗
What to watch
November 2029 (1)
Phase 1/2Non-Hodgkin LymphomaRecruiting
Est. primary completion 2029-11-30 · NCT05533775 · CT.gov ↗
What to watch
December 2029 (2)
Phase 2Systemic Sclerosis in AdultsNot yet recruiting
Est. primary completion 2029-12 · NCT07842523 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaNot yet recruiting
Est. primary completion 2029-12-01 · NCT07690891 · CT.gov ↗
What to watch
2030 (5)
January 2030 (2)
Phase 2Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Lymphoma, Lymphoma, B-CellNot yet recruiting
Est. primary completion 2030-01-01 · NCT07502872 · CT.gov ↗
What to watch
Phase 1/2Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Obinutuzumab βNot yet recruiting
Est. primary completion 2030-01-30 · NCT07696377 · CT.gov ↗
What to watch
July 2030 (2)
Phase 3Follicular LymphomaNot yet recruiting
Est. primary completion 2030-07 · NCT07719855 · CT.gov ↗
What to watch
Phase 2Diffuse Large B Cell Lymphoma (DLBCL)Not yet recruiting
Est. primary completion 2030-07-21 · NCT07599423 · CT.gov ↗
What to watch
November 2030 (1)
Phase 2Follicular LymphomaNot yet recruiting
Est. primary completion 2030-11-01 · NCT06961500 · CT.gov ↗
What to watch
2031 (4)
April 2031 (1)
Phase 3Follicular LymphomaRecruiting
Est. primary completion 2031-04 · NCT05929222 · CT.gov ↗
What to watch
June 2031 (1)
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2031-06-01 · NCT06967610 · CT.gov ↗
What to watch
July 2031 (1)
Phase 2Chronic Lymphocytic LeukemiaNot yet recruiting
Est. primary completion 2031-07-01 · NCT07887061 · CT.gov ↗
What to watch
December 2031 (1)
Phase 2Relapsed /Refractory DLBCLNot yet recruiting
Est. primary completion 2031-12 · NCT07634289 · CT.gov ↗
What to watch
2032 (3)
January 2032 (1)
Phase 1Non-Hodgkin LymphomaActive not recruiting
Est. primary completion 2032-01 · NCT06824701 · CT.gov ↗
What to watch
April 2032 (1)
Phase 2Mantle Cell Lymphoma, Mantle Cell Lymphoma RefractoryRecruiting
Est. primary completion 2032-04 · NCT05833763 · CT.gov ↗
What to watch
May 2032 (1)
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2032-05-31 · NCT06544785 · CT.gov ↗
What to watch
2033 (2)
May 2033 (1)
Phase 1/2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2033-05 · NCT07520006 · CT.gov ↗
What to watch
November 2033 (1)
Phase 2/3Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Refractory Burkitt Lymphoma …Recruiting
Est. primary completion 2033-11-01 · NCT07724457 · CT.gov ↗
What to watch
2037 (1)
November 2037 (1)
Phase 3Follicular LymphomaActive not recruiting
Est. primary completion 2037-11 · NCT06191744 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

November 2026FDA action dateFDA decision on Gazyva in primary membranous nephropathy expected by November 2026
US, FDA · Source ↗
November 2026ApprovalFDA approves Gazyva in primary membranous nephropathy
US, FDA · Source ↗

Recent

15 July 2026Priority reviewFDA grants Priority Review to Gazyva sBLA in primary membranous nephropathy
US, FDA · Source ↗